ACTRN12608000428369已完成1 期
The effect of the glucagon-like peptide-1 analogue, exenatide, on duodenal motility and flow events, and small intestinal transit in healthy humans and type 2 diabetes mellitus.
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 70 Years（—）
- 性别
- All
入选标准
- •Healthy subjects:
- •1. Body mass index (BMI) 19 - 25 kg/m2
- •Type 2 diabetic patients:
- •1. Body mass index (BMI) 19 - 35 kg/m2
- •2. Type 2 diabetes (World Health Organisation (WHO) criteria) managed by diet alone (i.e no oral hypoglycaemic drugs or insulin)
排除标准
- •History of gastrointestinal surgery (except appendicectomy)
- •1. Medication which may affect gastrointestinal motor function, specifically: opiates, anticholinergics, levodopa, calcium-channel antagonists, beta blockers, clonidine, nitrates, tricyclic antidepressants, selective serotonin re-uptake inhibitors, phosphodiesterase type 5 inhibitors, sumatriptan, metoclopramide, domperidone, cisapride, tegaserod, erythromycin
- •2. Other significant illness, including epilepsy, cardiovascular or respiratory disease
- •3. Pregnancy or lactation
- •4. Evidence of drug abuse, consumption of more than 20 g alcohol or 10 cigarettes per day
- •5. Regular gastrointestinal symptoms (as assessed by a validated upper gastrointestinal symptom questionnaire)
- •6. Autonomic nerve damage (as assessed by standardised cardiovascular reflex tests)
研究者
相似试验
进行中（未招募）
1 期
iraglutide to Short Bowel Syndrome, a cross-over studyShort bowel syndrome (SBS) is a clinical situation with reduced absorptive mucosal surface due to extensive surgical resection. SBS leads to increased intestinal losses of fluids and electrolytesrestricted oral/enteral nutrition to reduce intestinal lossesdisease-related hypophagialack of adaptive hyperphagiaaccelerated gastrointestinal transit timeMedDRA version: 19.1Level: PTClassification code 10049416Term: Short-bowel syndromeSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2015-000825-35-DKRigshospitalet Blegdamsvej16
进行中（未招募）
1 期
GLP-1 and persons without stroke.EUCTR2016-001221-14-DKHerlev Gentofte Hospital
进行中（未招募）
1 期
GLP-1 and strokeMedDRA version: 19.1Level: PTClassification code 10061256Term: Ischaemic strokeSystem Organ Class: 10029205 - Nervous system disordersStrokeEUCTR2016-001219-18-DKHerlev Gentofte Hospital30
已完成
2 期
Does exogenous glucagon-like peptide-1 (GLP-1) attenuates the glycaemic response to small intestinal nutrient in critically ill patients with pre-existing type-2 diabetes?Blood GlucoseType-2 DiabetesMetabolic and Endocrine - DiabetesACTRN12610000185066Adam Deane10
已完成
2 期
Exogenous glucagon-like peptide-1 (GLP-1) attenuates the glycaemic response to small intestinal nutrient in the critically ill.Blood GlucoseMetabolic and Endocrine - Other metabolic disordersACTRN12609000093280Adam Deane8